Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, Fenwick K, Grigoriadis A, Ashworth A, Pritchard-Jones K, Brown KW, Vujanic GM, Jones C.

Clin Cancer Res. 2008 Dec 1;14(23):7635-44. doi: 10.1158/1078-0432.CCR-08-1620.

2.

Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.

Fukuzawa R, Anaka MR, Heathcott RW, McNoe LA, Morison IM, Perlman EJ, Reeve AE.

J Pathol. 2008 Aug;215(4):377-87. doi: 10.1002/path.2366.

PMID:
18484682
3.

Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors.

Fukuzawa R, Reeve AE.

J Pediatr Hematol Oncol. 2007 Sep;29(9):589-94. Review.

PMID:
17805030
4.

Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Charles AK, Brown KW, Berry PJ.

Am J Pathol. 1998 Sep;153(3):991-1000.

5.

Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.

Yun K, Molenaar AJ, Fiedler AM, Mark AJ, Eccles MR, Becroft DM, Reeve AE.

Lab Invest. 1993 Nov;69(5):603-15.

PMID:
7504120
7.

Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.

Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.

Mol Cancer Res. 2005 Sep;3(9):493-502.

8.

Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, Perlman EJ.

Neoplasia. 2012 Aug;14(8):742-56.

9.

Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.

Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C.

Clin Cancer Res. 2009 Apr 15;15(8):2723-30. doi: 10.1158/1078-0432.CCR-08-1898. Epub 2009 Mar 24.

10.

Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis.

Okamoto K, Morison IM, Taniguchi T, Reeve AE.

Proc Natl Acad Sci U S A. 1997 May 13;94(10):5367-71.

11.

Expression of the RNA component of telomerase in Wilms tumor and nephrogenic rest recapitulates renal embryogenesis.

Yashima K, Maitra A, Timmons CF, Rogers BB, Pinar H, Shay JW, Gazdar AF.

Hum Pathol. 1998 May;29(5):536-42.

PMID:
9596280
12.

Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.

Guertl B, Ratschek M, Harms D, Jaenig U, Leuschner I, Poremba C, Hoefler G.

Hum Pathol. 2003 Mar;34(3):278-81.

PMID:
12673563
13.

Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.

Beckwith JB, Kiviat NB, Bonadio JF.

Pediatr Pathol. 1990;10(1-2):1-36. Review.

PMID:
2156243
14.

Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C.

Cancer Res. 2006 Dec 1;66(23):11148-55.

15.

Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.

Satoh Y, Nakadate H, Nakagawachi T, Higashimoto K, Joh K, Masaki Z, Uozumi J, Kaneko Y, Mukai T, Soejima H.

Br J Cancer. 2006 Aug 21;95(4):541-7. Epub 2006 Aug 8.

16.

Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.

Natrajan R, Warren W, Messahel B, Reis-Filho JS, Brundler MA, Dome JS, Grundy PE, Vujanic G, Pritchard-Jones K, Jones C.

J Clin Pathol. 2008 Jan;61(1):95-102. Epub 2007 Mar 16.

PMID:
17369505
17.

Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience.

Vujanić GM, Apps JR, Moroz V, Ceroni F, Williams RD, Sebire NJ, Pritchard-Jones K.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26547. Epub 2017 Apr 6.

PMID:
28383760
18.

Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms' tumorigenesis and epigenetic heterogeneity.

Ohlsson R, Cui H, He L, Pfeifer S, Malmikumpu H, Jiang S, Feinberg AP, Hedborg F.

Cancer Res. 1999 Aug 15;59(16):3889-92.

19.

Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.

Yun K, Fidler AE, Eccles MR, Reeve AE.

Cancer Res. 1993 Nov 1;53(21):5166-71.

20.

Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.

Sigamani E, Wari MN, Iyer VK, Agarwala S, Sharma A, Bakhshi S, Dinda A.

Pediatr Surg Int. 2013 Mar;29(3):223-7. doi: 10.1007/s00383-012-3254-8. Epub 2013 Jan 5.

PMID:
23292539

Supplemental Content

Support Center